Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Olaparib'

Olaparib published presentations and documents on DocSlides.

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing
by alexa-scheidler
Phase I Study of Olaparib and Temozolomide, in pa...
Case Discussion: Second
Case Discussion: Second
by celsa-spraggs
Opinion. 55 year-old woman with . recurrent . ova...
Please note, these are the actual video-recorded
Please note, these are the actual video-recorded
by blindnessinfluenced
proceedings from the live CME event and may includ...
by littleccas
actual. . video-recorded proceedings from the . l...
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
by zen
knowledge. ). Incorporate evidence-based research ...
Ovarian cancer update Kentucky cancer Registry
Ovarian cancer update Kentucky cancer Registry
by danika-pritchard
9/8/2016 . Erica . Takimoto. , D.O., F.A.C.O.O.G....
Updates in Ovarian Cancer Care
Updates in Ovarian Cancer Care
by tatiana-dople
Lisa McCluskey, MD. Gynecologic Oncologist. June ...
PARP Inhibitors This program will include a discussion of off-label treatment and investigational a
PARP Inhibitors This program will include a discussion of off-label treatment and investigational a
by conchita-marotz
PARP Inhibitors: What Do We know?. PARP Inhibitor...
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing
by karlyn-bohler
Phase I Study of Olaparib and Temozolomide, in pa...
PARP Inhibitors and Cancer: What Do You Need to Know?
PARP Inhibitors and Cancer: What Do You Need to Know?
by pasty-toler
This program will include a discussion of off-lab...
The Nurse View: Clinical Considerations in the Management of
The Nurse View: Clinical Considerations in the Management of
by natalia-silvester
BRCA. -Mutated Advanced Ovarian Cancer. Moderator...
NEw developments IN gynecological Oncology
NEw developments IN gynecological Oncology
by cheryl-pisano
highlights from the. EUROPEAN . society . of med...
Patient Selection for PARP
Patient Selection for PARP
by sherrill-nordquist
Inhibitors:. Purpose and Practicalities . Present...
Updates in Ovarian Cancer Care
Updates in Ovarian Cancer Care
by ellena-manuel
Lisa McCluskey, MD. Gynecologic Oncologist. June ...
by medshair
Five-year . survival. 15%. 30%. 40%. ?50%?. First ...
Genomic Prostate Cancer Testing for Olaparib
Genomic Prostate Cancer Testing for Olaparib
by abigail
Laura Yarram-Smith . Solid Tumour Lead SWGLH. J...
GU CONNECT PARP inhibitors in Prostate Cancer
GU CONNECT PARP inhibitors in Prostate Cancer
by jocelyn
Latest developments. . Prof.. . Neeraj Agarwal, ...
Year in Review Prostate Cancer
Year in Review Prostate Cancer
by faith
Emmanuel . S . Antonarakis. , MD. Professor of Onc...
What Clinicians Want to Know:
What Clinicians Want to Know:
by violet
Understanding the Factors Affecting the Optimal Di...